Serotonergic neurotoxicity of methylenedioxyamphetamine and methylenedioxymetamphetamine

Advances in Experimental Medicine and Biology

Volumn 500, Issue , 2001, Pages 397-406

  Monks, Terrence J ^a   Bai, Fengju ^a   Timothy Miller, R ^a   Lau, Serrine S ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; DOPAMINE; SEROTONIN RECEPTOR;

CONFERENCE PAPER; DRUG ABUSE; DRUG EFFECT; DRUG MECHANISM; NEUROTOXICITY; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM;

EID: 0035700216     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-0667-6_62     Document Type: Conference Paper

References (58)

1. The properties of 3,4-methylenedioxyamphetamine (MDA). I. A review of the literature
2. Chemistry and pharmacology of hallucinogens, entactogens and stimulants
3. Increasing use of ecstasy (MDMA) and other hallucinogens on a college campus
4. New variety of street drugs poses growing problem
5. Incidence of recreational use of 3,4-methylenedioxymethamphetamine (MDMA, "ECSTACY") on an undergraduate campus
6. Hallucinogens
7. Information on "ecstacy"
8. Chronic paranoid psychosis after misuse of MDMA
9. Pharmacology of p-chloroamphetamine and analogs
10. Hallucino-genic amphetamine selectively destroys brain serotonin nerve terminals
11. Lasting effects of 3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: Neurochemical observations
12. Cytopathologic features indicitive of 5-hydroxytryptamine axon degeneration are observed in rat brain after administration of D- and L-methylenedioxyamphetamine
13. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine
14. Effects of benzylpiperazine derivatives on the neurotoxicity of 3,4-methylenedioxymethamphetamine in rat brain
15. L-Dopa potentiation of the serotonergic deficits due to a single administration of 3,4-methylenedioxymethamphetamine, p-chloroamphetamine or methamphetamine to rats
16. Toxicity and deaths from 3,4-methylenedioxymethamphetamine
17. Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine
18. 2 receptors
19. 2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: Reversal by L-DOPA
20. Toxic effects of MDMA on central serotonergic neurons in primate: Importance of route and frequency of drug administration
21. Direct intracerebral administration of MDA and MDMA does not produce serotonin neurotoxicity
22. Direct central effects of acute methylenedioxymethamphetamine on serotonergic neurons
23. Lack of serotonin neurotoxicity after intraraphe microinjection of (+)-3,4-methylenedioxymethamphetamine (MDMA)
24. Influence of inducers and inhibitors on the metabolism in vitro and neurochemical effects in vivo of MDMA
25. Major metabolites of 3,4-methylenedioxyamphetamine (MDA) do not mediate its toxic effects on brain serotonin neurons
26. Synthesis and neurotoxicological evaluation of putative metabolites of theserotonergic neurotoxin 2-(methylamine)-1-[3,4-methylenedioxyl]propane [(methylenedioxy)methamphetamine]
27. Effects of 3,4-dihydroxymethamphetamine and 2,4,5-trihydroxymethamphetamine, two metabolites of 3,4-methylenedioxymethamphetamine, on central serotonergic and dopaminergic systems
28. Long-term alteration in the central in the central monoaminergic systems of the rat by 2,4,5-trihydroxyamphetamine, but not by 2-hydroxy-4,5-methylenedioxymethamphetamine or 2-hydroxy-4,5-methylenedioxyamphetamine
29. Metabolism of β-3,4-methylenedioxyamphetamine in the rat
30. α-Methyldopamine, a key intermediate in the metabolic disposition of 3,4-methylenedioxyamphetamine in vivo in dog and monkey
31. In vivo and in vitro metabolism of 3,4-(methylenedioxy)methamphetamine in the rat: Identification of metabolites using an ion trap detector
32. Metabolism of methylenedioxyphenyl compounds by rabbit liver preparations. Participation of different cytochrome P450 isozymes in the demethyleneation reaction
33. Cytochrome P450 isozymes responsible for the metabolic activation of methylenedioxymethamphetamine (MDMA) in rat
34. Metabolism of methylenedioxymethamphetamine: Formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct
35. Transformation of dopamine and α-methyldopamine by NG108-15 cells: Formation of thiol adducts
36. Biological reactivity of polyphenolic-glutathione conjugates
37. Hepatic low-level chemiluminesence during redox cycling of menadione and the menadione-glutathione conjugate: Relation to glutathione and NAD(P)H: Quinone reductase (DT diaphorase) activity
38. 2-Bromo-(diglutathion-S-yl)hydroquinone nephrotoxicity: Physiological, biochemical and electrochemical determinants
39. Effect of 5-(Glutathion-S-yl)-α-methyldopamine on dopamine, serotonin and norepinepherine concentrations following intracerebroventricular administration to male Sprague-Dawley rats
40. 2,5-bis-(Glutathion-S-yl)-α-methyldopamine, a putative metabolite of (±)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations
41. A The role of glutathione in neuroprotection and neurotoxicity
42. Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity
43. Metabolism of 5-(glutathion-S-yl)-α-methyldopamine following intracerebroventricular administration to male Sprague-Dawley rats
44. Oxidative cyclization, 1,4-benzothiazine formation and dimerization of 2-bromo-3-(glutathion-S-yl)hydroquinone
45. Oxidation and acetylation as determinants of 2-bromocystein-S-ylhydroquinone-mediated nephrotoxicity
46. Glutathione and N-acetylcysteine conjugates of α-methyldopamine produce serotonergic neurotoxicity. Possible role in methylenedioxyamphetamine-mediated neurotoxicity
47. Superoxide radicals mediate the biochemical effects of methylenedioxymethamphetamine (MDMA): Evidence from using CuZn-superoxide dismutase transgenic mice
48. The blood-brain barrier: Morphology, molecules, and neurothelin
49. Amino acid assignment to one of three blood-brain barrier amino acid carriers
50. Morphological changes in kidneys of rats exposed to dichloroacetylene-ether
51. Neurotoxic effects of dichloroacetylene
52. Brain uptake of S-(1,2-dichlorovinyl)-glutathione and S-(1,2-dichlorovinyl)-L-cysteine
53. Evidence for carrier-mediated transport of glutathione across the blood-brain barrier in the rat
54. γ-Glutamyl transpeptidase activity in brain microvessels exhibits regional heterogeneity
55. Blood-brain barier restriction of of peptides and the low uptake of enkephalins
56. Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes
57. Human class Mu glutathione transferases, in particular isoenzyme M2-2 catalyze detoxication of the dopamine metabolite aminochrome